SCHEMBL12201992

SCHEMBL12201992

O=C(COc1ccc(C(=O)c2cc3ccccc3s2)c(Cl)c1Cl)Nc1ccc2cnccc2c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 8/20 0.59
GALR3 O60755 1/20 0.42
LMNA P02545 1/20 0.42
STAT3 P40763 1/20 0.42
IMPDH2 P12268 2/20 0.41
NPC1 O15118 3/20 0.41
PRNP P04156 2/20 0.41
KCNH2 Q12809 1/20 0.41
POLB P06746 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ROCK2 O75116 1/20 0.40
TP53 P04637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12201990 0.85 NOTUM (0.60) NOTUMGALR3LMNASTAT3IMPDH2
SCHEMBL1105179 0.82 CYP2C9 (0.57) NOTUMGALR3LMNASTAT3NPC1
SCHEMBL12201988 0.81 NOTUM (0.66) NOTUMLMNAIMPDH2NPC1POLB
SCHEMBL12201997 0.76 NOTUM (0.59) NOTUMLMNAMAPTCYP2C9TP53
SCHEMBL12201983 0.76 NOTUM (0.83) NOTUMLMNAIMPDH2NPC1RAB9A
SCHEMBL20353550 0.75 IMPDH2 (0.57) IMPDH2NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL1123774 0.75 NOTUM (0.57) NOTUMLMNANPC1POLBMAPT
SCHEMBL5624271 0.74 POLB (0.48) LMNANPC1POLBRAB9AMAPT
SCHEMBL12201980 0.74 NOTUM (0.63) NOTUMLMNAIMPDH2NPC1POLB
SCHEMBL12202001 0.72 NOTUM (0.61) NOTUMGALR3LMNASTAT3IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034943-B2 6-aminoisoquinoline compounds AERIE PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-8034943-B2 6-aminoisoquinoline compounds AERIE PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-20100137364-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
US-20100137364-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
US-7671205-B2 6-aminoisoquinoline compounds AERIE PHARMACEUTICALS, INC. (US) 2010-03-02 US disclosed
US-7671205-B2 6-aminoisoquinoline compounds AERIE PHARMACEUTICALS, INC. (US) 2010-03-02 US disclosed
US-20070173530-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed
US-20070173530-A1 6-Aminoisoquinoline Compounds AERIE PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137364-A1 6-Aminoisoquinoline Compounds COQ8A, PGC, AGK NOTUM 3635/4885GALR3 1298/4885LMNA 2665/4885
US-20070173530-A1 6-Aminoisoquinoline Compounds COQ8A, PGC, AGK NOTUM 3635/4885GALR3 1298/4885LMNA 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.